PRP vs PRF: Differences, Cost & Which Is Right (2026)

*FDA status: PRP and PRF are not FDA-approved drugs. The centrifuge systems and collection tubes used to prepare them are regulated as devices, and the aesthetic uses described here, including facial rejuvenation, under-eye treatment, hair thinning and microneedling, are off-label. Both are autologous, meaning they are made from your own blood. The evidence is promising but limited. Educational content, not medical advice.*

Platelet-rich plasma and platelet-rich fibrin are the two most common autologous, or self-derived, injectables in aesthetic medicine. Both start the same way: a small blood draw, a spin in a centrifuge, and a concentrated platelet product delivered back into your skin or scalp. The marketing around them frequently frames PRF as a straight upgrade on PRP, and some clinics price it that way. The clinical picture is more nuanced. The two products differ in how they are processed, how quickly they release their growth factors, how they behave once inside tissue, how long a clinician has to work with them, and how much published evidence supports each specific use. This guide compares them attribute by attribute so you can have a precise conversation with a qualified provider rather than choosing on a brand name.

One expectation is worth setting before anything else: neither PRP nor PRF is a filler, and neither produces an immediate visible change. Both work by stimulating your own repair and collagen-building processes, so improvement appears gradually over roughly four to twelve weeks and usually requires a short series of sessions followed by periodic maintenance. Anyone promising a dramatic single-session transformation, permanent correction, or guaranteed hair regrowth is overselling what the published evidence supports. Realistic expectations are the single biggest predictor of whether people end up satisfied with platelet therapies.

PRP and PRF at a glance

The shortest honest answer is that PRP and PRF are close relatives rather than rivals. PRP, platelet-rich plasma, is produced with a fast centrifuge spin in a tube containing an anticoagulant such as sodium citrate or ACD-A. The anticoagulant keeps the product liquid, so it stays injectable through a fine needle and the clinician has a comfortable working window. PRF, platelet-rich fibrin, is produced with a slower, gentler spin in a plain tube with no anticoagulant and no activator. Because nothing is added, the blood begins to clot naturally, and platelets, white cells and, according to laboratory characterization studies, a small share of circulating stem cells become trapped inside a three-dimensional fibrin mesh.

That single processing decision drives nearly every practical difference that follows: how fast growth factors arrive, how long they keep arriving, how thick the product is, whether it can be layered or shaped, and how quickly it must be used after the draw. PRP carries the deeper research base across dermatology, orthopedics and hair medicine, largely because it has been studied for longer. PRF is newer, additive-free, and increasingly favored by injectors for delicate facial work. Neither preparation has been shown in high-quality head-to-head trials to be superior across the board, and any clinic claiming otherwise is running ahead of the data.

What PRP and PRF have in common

Everything upstream of the centrifuge is identical. A provider draws a small volume of your blood, usually somewhere between 10 and 60 milliliters depending on how many areas are being treated, and spins it to separate red cells from the platelet-rich fraction. Platelets are not merely clotting cells: their alpha granules carry a payload of signaling proteins including platelet-derived growth factor, transforming growth factor beta, vascular endothelial growth factor, epidermal growth factor and insulin-like growth factor. Concentrating those proteins and redelivering them into tissue is the entire premise of both treatments. The intended biological effect is the same in each case: recruit repair cells, encourage new small blood vessels, and stimulate fibroblasts to lay down fresh collagen.

The clinical experience is also similar. Both are delivered by fine-needle or cannula injection, by topical application over a microneedling pass, or by a combination of the two. Both usually involve a numbing cream, take roughly thirty to sixty minutes door to door including the draw and the spin, and leave most people with mild redness and swelling for a day or two. Both are typically prescribed as a series, commonly three sessions spaced four to six weeks apart, with maintenance every six to twelve months. Both are autologous, so true allergic reaction and immune rejection are extremely unlikely. And critically, both share the same regulatory position in the United States: the devices used to prepare them fall under device regulation, while the aesthetic uses people actually book them for are off-label. Neither is an FDA-approved cosmetic drug, and neither is covered by insurance for cosmetic indications.

How preparation creates the difference

For PRP, blood is collected into a tube pre-loaded with an anticoagulant and spun hard, frequently in two stages. The first spin separates red cells from plasma, and a second, faster spin concentrates the platelets into a smaller plasma volume. Some protocols then add an activator such as calcium chloride or thrombin to trigger release on demand. The result is a stable liquid that a clinician can draw up, split across several syringes, and inject unhurriedly over multiple areas. Because the platelets are chemically prevented from clotting and are then released more or less at once, growth factor delivery is front-loaded: a large fraction arrives within the first hours after injection.

For PRF, blood is collected into a plain tube with nothing in it and spun at a lower relative centrifugal force for a shorter time. Without an anticoagulant, the natural coagulation cascade proceeds while the tube is spinning. Fibrinogen converts to fibrin and forms a soft three-dimensional scaffold, and the platelets, a higher share of white cells and some circulating stem cells are physically caught inside that mesh. The scaffold then behaves like a slow-release sponge, degrading over days and liberating growth factors progressively rather than all at once. Laboratory work generally shows a lower initial spike from PRF but a higher cumulative release measured across the following week to ten days. The contrast is often summarized this way in the literature: with activated PRP the great majority of stored growth factors are liberated shortly after activation, whereas PRF meters the same payload out slowly. Whether that difference in release kinetics translates into a better clinical outcome for any specific aesthetic indication is exactly the question the published trials have not yet answered.

Two practical consequences follow. First, PRF has a short usable life: once it starts to gel the clock is running, so it must be drawn up and delivered within minutes, which demands a tighter clinic workflow and a provider who is comfortable working quickly. Second, PRF can be manipulated into forms PRP cannot, including a thicker gel, a compressed membrane, or heated variants marketed under names such as albumin gel or EZ-Gel that some injectors use for longer-lasting soft tissue support. Protocol variation between clinics is wide. Centrifuge speed, spin time and tube type all change the final product, which is a major reason published study results are difficult to compare with one another.

Key differences in onset, duration and evidence

In terms of what a patient actually notices, the timelines are closer than the marketing suggests. Neither product delivers a visible result on day one. Both stimulate collagen remodeling that takes weeks, so the meaningful comparison is not onset but durability and cumulative effect. The theoretical case for PRF is that a longer growth factor release should produce a stronger and longer-lasting regenerative signal. The theoretical case for PRP is that it has been refined and studied for longer, and that a rapid, high-concentration burst may be entirely sufficient for the biology involved.

The published evidence does not settle the argument. A 2025 systematic review in the Journal of Cosmetic Dermatology pooled fourteen studies of periorbital platelet therapy, ten involving PRP and five involving PRF, with one study assessing both, and concluded that current data do not support the superiority of one modality over the other. Within that review, PRF tended to perform better for skin texture, skin density, crepiness and fine wrinkling, while PRP had stronger evidence for improving hyperpigmentation and dark circles, with one trial reporting a melanin reduction of around 47 percent. Durability was a genuine weak point for PRF: the authors noted that PRF improvements often diminished by six months, and in one included study an early gain in canthal smoothness had disappeared entirely by that timepoint, whereas PRP's pigmentation benefits were sustained at comparable intervals. Separately, a 2022 comparative study in Archives of Dermatological Research reported that improvement in atrophic acne scars was significantly greater with fluid PRF, alone or combined with microneedling, than with PRP.

Read those results alongside the limitations the authors themselves flag. Only a small minority of the pooled studies used objective measurement rather than subjective patient satisfaction scores, most PRF studies followed patients for only one to three months, and centrifuge speeds, spin durations and tube characteristics varied so widely between studies that direct comparison is compromised. The American Society of Plastic Surgeons has made the same point about platelet therapy for cosmetic facial procedures: reported results are largely positive, but the absence of standardized preparation and injection protocols is a serious limitation on the strength of that evidence. In short, PRF is plausible and promising, not proven superior, and honest guidance should say so.

Which option suits which concern

Under the eyes, many injectors reach for PRF. The reasoning is practical rather than dogmatic: the gel-like consistency sits more predictably in thin periorbital skin, the additive-free preparation avoids introducing an anticoagulant into a delicate area, and the sustained release suits tissue that remodels slowly. PRF can soften mild hollowing, crepiness and fine lines, but it is not a volumizer. For a true tear-trough deficit, hyaluronic acid filler remains the tool that adds structural volume, and some injectors stage the two treatments rather than choosing between them. PRP still has the better evidence for pigment-driven dark circles, so the right choice depends on whether your concern is shadow, texture or lost volume. All periorbital use of either product is off-label.

For overall skin quality, both pair well with microneedling, and a clinical trial registered on ClinicalTrials.gov (NCT06452667) was set up to compare PRF against PRP for microneedling treatment of facial photoaging. No results have been posted for it, and the registry currently lists its status as unknown, which is itself a fair summary of the field: the question is genuinely open rather than settled. For acne scarring, the limited comparative data modestly favors PRF. For hair thinning, PRP has by far the larger body of evidence, including research highlighted by the American Academy of Dermatology showing benefit in pattern hair loss, and it remains the more defensible choice if hair is your primary goal; PRF is increasingly used for scalp work, but the supporting literature is thinner. If your concern is deep static folds, significant volume loss or advanced skin laxity, neither platelet therapy is the right primary treatment, and an honest provider will tell you that before taking a deposit.

Safety, side effects and who is not a candidate

Safety is a genuine shared strength, and neither preparation has been shown to be meaningfully safer than the other. If pressed, PRF has a theoretical edge because nothing at all is added to the tube, so there is no anticoagulant or activator in the injected product; that is an argument from first principles rather than from comparative safety data, and the reported adverse events for both are the same short list. Because the material is your own blood with nothing foreign added, allergic reaction and immune rejection are extremely unlikely, and the systematic literature on periorbital use describes favorable safety profiles with only mild, transient adverse effects. The realistic side effects for both are bruising, swelling, redness, tenderness and temporary lumpiness at injection points, generally resolving within two to seven days. Under-eye swelling can persist longer than people expect, occasionally a week or more, which matters if you have an event coming up. PRF, being thicker, can feel firmer under thin skin during the first few days.

The rarer risks deserve naming plainly. Infection is uncommon but possible whenever the skin is broken, which is a concrete reason to insist on sterile technique and a licensed clinical setting rather than a mobile or unlicensed provider. Persistent nodules have been reported after periorbital injection of platelet products. Any injection near the eye carries a very rare risk of vascular events, so periorbital work belongs with an experienced injector who knows the anatomy of the area. Because there is no standardized commercial formulation, the quality and concentration of the product genuinely varies between clinics, and that variability is part of the risk picture.

Platelet therapy is generally not appropriate if you have a platelet function disorder, a low platelet count, an active blood-borne cancer or hematological malignancy, an active infection at the treatment site or systemically, or severe anemia. Ongoing anticoagulant or antiplatelet therapy, pregnancy and breastfeeding, and uncontrolled autoimmune or chronic liver disease all warrant a medical conversation before you proceed. The FDA has separately warned consumers that many products marketed as regenerative medicine therapies are unapproved and that promotional claims can outrun the evidence supporting them, which is a useful lens for reading any clinic's marketing language about either preparation.

What PRP and PRF cost

Published price ranges for both sit broadly between about four hundred and fifteen hundred dollars per session in the United States, with facial and under-eye treatments commonly quoted toward the middle of that band and scalp or multi-area protocols running higher. We do not publish fixed prices, because pricing is genuinely provider-specific and any single number would mislead you. The honest framing is that PRP and PRF cost roughly the same. PRF is sometimes marginally cheaper on paper because the tubes contain no anticoagulant or additive and the protocol involves a single spin, but that saving is small relative to the clinician's time and the clinic's overhead, and some practices price PRF higher precisely because it is marketed as the newer option.

Several factors move the number far more than the choice between PRP and PRF does. Geography is the biggest single driver, with major metropolitan markets running well above regional averages. Injector credentials matter, since a physician-performed treatment typically costs more than one delegated to a nurse injector. The volume of blood drawn, the number of areas treated, whether microneedling is combined with injection, and whether a specialized tube system or proprietary device kit is used all add to the total. Most importantly, ask for the price of the full recommended plan rather than a single visit, because both treatments are almost always advised as a series of two to four sessions plus maintenance. A cheap first session inside an expensive package is not a saving. Cosmetic use of either product is not covered by insurance.

How to choose and what to ask your provider

Because the head-to-head evidence is inconclusive, the most useful decision rule is to choose the injector first and let them recommend the preparation. An experienced provider who performs both will select based on your concern, your skin thickness, the treatment area and their own protocol, and that judgment is worth more than a brand preference formed from social media. Be wary of any clinic that offers only one and describes the other as obsolete or unsafe. Both remain in mainstream use, and the honest answer to which is better is that it depends on the indication, the area and the operator.

Take specific questions to the consultation. Ask what the provider expects to achieve for your particular concern and, just as usefully, what it will not do. Ask whether PRP or PRF is being recommended and why, in terms of your anatomy rather than in terms of what is newest. Ask about their preparation protocol, including tube type, spin speed and whether a single or double spin is used, since those choices determine the actual product you receive. Ask who performs the blood draw and the injection, and confirm their license and their training in the specific area being treated. Ask how many sessions are recommended, what maintenance looks like, and what the full plan costs. Ask to see unretouched before and after photographs of their own patients in the same area, taken in consistent lighting. Finally, ask what happens if you see no benefit, because for a subset of people platelet therapy simply does not produce a noticeable result, and a provider who acknowledges that honestly up front is a provider worth trusting.